Any current/future new fundraising through debt or equity?

The company is largely done with major Capex and does not currently plan any significant additional capital expenditure. Working capital requirements are expected to increase due to business expansion and extended credit periods to large pharma clients. The management is actively discussing and arranging working capital financing, primarily through debt. No plans for further equity dilution at present; working capital needs to be met through debt or other financing. Off-balance sheet financing options like invoice/bill discounting are being explored to fund receivables. Interest costs from suc

Any current/future capex/capital investment/strategic investment?

The company is largely done with major Capex; no large Capex planned currently. Minor investments may occur for small capacity changes or material-related extensions. Recent expansions include new plants in Oman and Bangalore for flexography business. Pharmaceutical packaging business is expanding with 3 new lines: tandem line, PVC/PVDC line, and Alu-Alu capacity expansion. The Wahren unit is undergoing capacity expansion from 8,000 tons to 20,000 tons; the new machine is in the last commissioning leg. They acquired high-value machines (PVC/PVDC and tandem) at discounted prices through NCLT. T

Future growth expectations in sales/revenue/volumes?

The company targets to achieve a revenue of ₹1000 crore within the next couple of years, aiming to double revenue annually. Capacity expansions include increasing Alu-Alu capacity from 8,000 to 20,000 tons, targeting over 50% utilization in FY27. PVDC and tandem line capacities are expected to contribute, with PVDC initially at 30-40% utilization in FY27. Order books currently exceed supply, indicating strong demand and supply-side constraints. New capacities and product lines (PVDC, tandem line) are expected to drive growth and diversify revenue streams. The company anticipates robust growth

Future growth expectations in earnings/operating earnings/profits/EPS?

The company aims to achieve a revenue of ₹1,000 crore over the next couple of years, targeting to double revenue annually. Profit growth has been strong, with a 68% CAGR and achieving ₹20+ crore PAT in the last financial year. For FY27 and FY28, the management expects: - Alu-Alu pharmaceutical packaging EBITDA margins in low teens (11-13%). - Flexography business margins to remain in high teens to low 20s. Despite recent pressure from aluminum price rises and expansion costs, long-term profit margins are expected to be stable or improve. Capacity expansions (including new machines and plan

Current/ Expected Orderbook/ Pending Orders?

The company carries 15-20 days of overflow orders, which are currently being rolled over into the next month due to capacity constraints. With the new capacity installation expected to start soon, the company anticipates being able to fulfill all client orders within the same month. There is constant pressure on production and consistent challenges due to capacity, but the expansion will help reduce fixed costs and improve margins. The order book consistently exceeds supply capacity, causing orders to spill into subsequent months, indicating strong demand. New client acquisitions are o

IN US

Sale is live|00:00:00left today

Creative Graphics Solutions India LtdQ4 FY27Industrial Products

Creative Graphics Solutions India Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹144P/E: 17.0Market Cap: ₹406 CrSector: Industrial Products

Management growth scorecard

Revenue

Category 1

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 1

→The company targets to achieve a revenue of ₹1000 crore within the next couple of years, aiming to double revenue annually.
→Capacity expansions include increasing Alu-Alu capacity from 8,000 to 20,000 tons, targeting over 50% utilization in FY27.
→PVDC and tandem line capacities are expected to contribute, with PVDC initially at 30-40% utilization in FY27.
→Order books currently exceed supply, indicating strong demand and supply-side constraints.
→New capacities and product lines (PVDC, tandem line) are expected to drive growth and diversify revenue streams.
→The company anticipates robust growth in FY27, leveraging overspill orders and new client acquisitions.
→Expects revenue potential of ₹700-750 crore from Wahren (Alu-Alu) and ₹200-250 crore from PVDC at full capacity.
→Expansion largely funded; working capital needs to be managed with debt and no immediate equity dilution planned.

Margin guidance

Category 3

→The company aims to achieve a revenue of ₹1,000 crore over the next couple of years, targeting to double revenue annually.
→Profit growth has been strong, with a 68% CAGR and achieving ₹20+ crore PAT in the last financial year.
→For FY27 and FY28, the management expects:
→ - Alu-Alu pharmaceutical packaging EBITDA margins in low teens (11-13%).
→ - Flexography business margins to remain in high teens to low 20s.
→Despite recent pressure from aluminum price rises and expansion costs, long-term profit margins are expected to be stable or improve.
→Capacity expansions (including new machines and plants) are anticipated to drive volume growth and better cost absorption, supporting future margin improvement.
→Near-term PAT may face temporary pressure due to expansions, but growth momentum and margin profile are expected to sustain or improve over time.
→Earnings per share (EPS) is likely to grow aligned with revenue growth and operational efficiencies post-expansions.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company is largely done with major Capex and does not currently plan any significant additional capital expenditure.
→Working capital requirements are expected to increase due to business expansion and extended credit periods to large pharma clients.
→The management is actively discussing and arranging working capital financing, primarily through debt.
→No plans for further equity dilution at present; working capital needs to be met through debt or other financing.
→Off-balance sheet financing options like invoice/bill discounting are being explored to fund receivables.
→Interest costs from such financing will be factored into pricing, implying the company or customers bear it.
→A materialization or breakthrough in bill discounting is expected within the next month.
→For at least the next 6 months, existing financing arrangements are considered sufficient. Further funding decisions will depend on working capital consumption and business growth.

Order book

Yes

→The company carries 15-20 days of overflow orders, which are currently being rolled over into the next month due to capacity constraints.
→With the new capacity installation expected to start soon, the company anticipates being able to fulfill all client orders within the same month.
→There is constant pressure on production and consistent challenges due to capacity, but the expansion will help reduce fixed costs and improve margins.
→The order book consistently exceeds supply capacity, causing orders to spill into subsequent months, indicating strong demand.
→New client acquisitions are ongoing, and there is no expected difficulty in absorbing the increased capacity and fulfilling orders.
→Overall, the company expects order fulfillment to improve significantly post capacity expansion, benefiting margin profiles and operational efficiency.

Capex plans

Yes

→The company is largely done with major Capex; no large Capex planned currently.
→Minor investments may occur for small capacity changes or material-related extensions.
→Recent expansions include new plants in Oman and Bangalore for flexography business.
→Pharmaceutical packaging business is expanding with 3 new lines: tandem line, PVC/PVDC line, and Alu-Alu capacity expansion.
→The Wahren unit is undergoing capacity expansion from 8,000 tons to 20,000 tons; the new machine is in the last commissioning leg.
→They acquired high-value machines (PVC/PVDC and tandem) at discounted prices through NCLT.
→The company is focused on executing existing expansion plans to reach 1000+ crores turnover in the next few years.
→Working capital requirements to be funded mainly via working capital debt; no immediate plan for equity dilution.

How does Creative Graphics Solutions India Ltd rank vs peers in Industrial Products?

Pro feature

1Creative Graphics Solutions India Ltd

Rev 1Mar 3

See full Industrial Products sector rankings

Want more stocks like Creative Graphics Solutions India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio